CTI Clinical Trial and Consulting Services Opens Geel, Belgium Office
CTI announced that is has opened an office in Geel, Belgium.
CTI Clinical Trial and Consulting Services (CTI), a multi-national, privately held, full-service contract research organization announces that is has opened an office in Geel, Belgium. The office is opened through the wholly-owned subsidiary, CTI Clinical Trial and Consulting Services Belgium SPRL. This is the company’s sixth new office opened this year, with additional new offices expected to be announced in the next several months.
“We have had CTI employees in Belgium for the past several years working on behalf of our pharmaceutical and biotechnology clients, but it felt like it was time to formalize an office in the country,” according to Patrick Earley, Vice President, International. “Belgium is desirable for clinical trials due to innovative regulatory agencies, as well as excellent academic centers and researchers, leading to rapid study start up timelines and high enrollment at sites.”
CTI has been working for over fifteen years in the drug development industry in North America, Europe, South America, and Pac-Asia, specializing in clinical research programs involving critically ill patient populations, and has more than 20 offices worldwide to serve more than 80 pharmaceutical, biotechnology, and medical device clients.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
